Here's what's coming. What these medicines actually do in the body. The BMI thresholds behind the weight-management licence, and why they shift for some groups. How the diabetes indication differs completely. And why none of this is ever just a form to fill in.
▶ Watch this as a film on SugarCoach TV — live 24/7
THE QUESTION — One jab, two very different reasons
Every week someone asks the same thing. Can I just get the jab. It sounds like a simple question. It isn't. Because GLP-1 medicines were licensed for two quite different jobs, with two different rulebooks, and neither of them is a shortcut for the last few pounds before a holiday. Tonight we're decoding the actual UK picture. Not opinion. Not TikTok. The licensing, the thresholds, and why a clinician has to sit in the middle of it.
WHAT IT IS — A borrowed gut hormone, turned up
GLP-1 stands for glucagon-like peptide-1, a hormone your gut already makes after you eat. It tells your pancreas to release insulin, slows how fast your stomach empties, and turns down appetite signals in the brain. The medicines mimic that hormone at higher, steadier levels than food alone ever produces. That's the whole trick. Not fat-burning, not magic. A borrowed signal, turned up.
TWO LICENCES — Same molecule, two separate rulebooks
Here's the bit that gets lost. Semaglutide and tirzepatide, the two GLP-1 medicines licensed in the UK, actually carry separate licences. One is for type 2 diabetes, to help manage blood sugar. One is for weight management, in people who meet specific criteria. Same molecule family, different job description, different rulebook for who qualifies. Mixing the two up is where most of the confusion starts.
BMI, DECODED — A screening tool, not a verdict
Body mass index is just weight against height, a rough population screening tool, not a verdict on any one body. Clinicians know its limits, it doesn't see muscle, frame, or where fat sits. But regulators needed some consistent measure to set a threshold, and BMI is what NICE guidance uses. Think of it as the door you have to reach, not the whole assessment.
THE THRESHOLD — Around 30, or 27 with a condition
For the weight-management licence, NICE guidance generally points to a BMI of around 30, classed as obese, or around 27 with a weight-related condition alongside it, something like high blood pressure or diabetes risk. Those are typical figures, services can vary slightly in how they're applied. It's a starting filter, not an automatic yes.
WHY IT SHIFTS — The number moves for a reason
Here's a detail most headlines skip. Health risk at a given BMI isn't identical across populations. NICE guidance recognises that people of South Asian, Black African, and African-Caribbean backgrounds tend to carry higher metabolic risk at lower BMI figures, so thresholds are often set around two and a half points lower for those groups. It's not a loophole, it's the guidance trying to be accurate about risk.
THE DIABETES ROUTE — A different licence, a different logic
The type 2 diabetes indication runs on a different logic entirely. It's prescribed to help manage blood glucose, alongside diet and other medication, and BMI isn't the gatekeeper in the same way. Someone with diabetes and a BMI in the twenties can still be a candidate. Weight loss often follows as a welcome side effect, but glycaemic control is the actual reason it's written up.
MORE THAN A NUMBER — The number gets you in the room
None of this happens with a calculator alone. A clinician is weighing blood pressure, cholesterol, kidney function, other medications, family history, even whether someone has a history of certain thyroid or pancreatic conditions where these drugs aren't suitable at all. The BMI number gets you into the room. What happens in the room is a much longer conversation than a checkout page ever could be.
THE LAST HALF STONE — Not what these medicines were built for
So why not for the last half stone. Because that's not what got licensed. These are medicines developed and tested for people carrying significant excess weight with real health risk attached, not for shifting a stubborn last few pounds before a wedding. The evidence base, the safety data, all of it was built around a different population, with a different risk profile.
THE OTHER SIDE — Every medicine has two sides
Every medicine has two sides. GLP-1s commonly reported side effects include nausea, reflux, constipation, and fatigue, usually easing over time but not always. For someone with significant obesity-related risk, that trade-off often makes sense. For someone chasing a small aesthetic change, the risk-benefit tips the other way. Regulators price that trade-off in when they decide who a medicine is actually for.
RISK, NOT LOOKS — A health calculation, not a styling one
Licensing bodies aren't in the business of appearance. They're weighing whether a medicine reduces real health risk, heart disease, stroke, diabetes progression, enough to justify its downsides across a population. That's a public health calculation, not a personal styling one. Which is exactly why the threshold sits where it does, and why it isn't designed to move for cosmetic preference.
OFF-LABEL, CAUTIOUSLY — A judgement call, not a default
Off-label prescribing exists in medicine generally, a clinician can sometimes prescribe outside the strict licence if they judge it appropriate for that individual. But that's a considered clinical judgement, made with full knowledge of someone's history, not a default option. It's exactly why this sits with a GP or pharmacist, not with a form you fill in and never speak to anyone about.
WHERE THE LINE CAME FROM — The evidence drew the line, not bureaucracy
The threshold numbers aren't arbitrary. They come from the populations these medicines were actually tested in during clinical trials, the people whose data proves the benefit outweighs the risk. Regulators license medicines for the group the evidence covers, not beyond it. Step outside that group and you're extrapolating from data that was never designed to cover you, which is precisely what proper assessment exists to catch.
A REAL ASSESSMENT — It takes time, on purpose
A real assessment looks like this. Weight and height history, not just today's number. Blood tests, blood pressure, sometimes a diabetes risk check. Questions about other conditions, other medications, family history, and what's actually driving the weight in the first place, because sleep, stress, and other medications all play a part. It takes time, on purpose, because the decision deserves it.
NOT A CHECKOUT — A form can't catch what a chat can
Clinicians get uneasy about checkout-style access because a tick-box form can't catch a contraindication nobody thought to ask about, or a subtler risk that only shows up in real conversation. It's not gatekeeping for its own sake, it's the difference between a medicine matched carefully to a person, and one sold to a set of symptoms on a screen, with nobody in the room.
THE GP'S JOB — Checking the criteria genuinely fit you
This is why the answer to am I eligible always comes back to a GP or pharmacist. They're not there to say no for the sake of it. They're checking the licence criteria genuinely fit you, weighing your specific history, and making sure you understand what you're starting, including how long it's meant to be used and what support sits alongside it. That's a conversation, not a form.
AFTER THE PRESCRIPTION — The prescription is one part of a plan
If a medicine is prescribed, that's not the end of the process, it's the start of another one. Follow-up checks, monitoring for side effects, adjusting alongside diet and activity changes, reviewing whether it's still the right call months in. Weight management support done properly is ongoing, not a single transaction. The prescription is one part of a longer plan, not the plan itself.
THE FOOD SIDE — The food job stays the same either way
Wherever you land on eligibility, the food side stays exactly the same job, every day, medicine or not. What's actually in your usual meals, where the hidden sugar sits, what a genuinely filling plate looks like. That's the conversation SugarCoach is built for, and it's one you can start today, whatever a GP eventually decides about anything else.
Could I just ask for a GLP-1 to lose my last half stone?
That's a question for your GP or pharmacist. Meanwhile, ask the coach for a food plan that tackles it without medication. (answer generated by SugarCoach, the AI coach)
General lifestyle education, not medical advice — personal medical decisions belong with your GP or pharmacist.